According to Amedisys's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 1.12747. At the end of 2023 the company had a P/S ratio of 1.08.
Year | P/S ratio | Change |
---|---|---|
2023 | 1.08 | -11.78% |
2022 | 1.22 | -48.78% |
2021 | 2.38 | -48.69% |
2020 | 4.65 | 68.61% |
2019 | 2.76 | 22.35% |
2018 | 2.25 | 93.1% |
2017 | 1.17 | 17.15% |
2016 | 0.9956 | -3.53% |
2015 | 1.03 | 26.07% |
2014 | 0.8186 | 115.99% |
2013 | 0.3790 | 60.42% |
2012 | 0.2362 | 8.16% |
2011 | 0.2184 | -63.55% |
2010 | 0.5992 | -33.81% |
2009 | 0.9053 | -3.67% |
2008 | 0.9398 | -48.73% |
2007 | 1.83 | 16.98% |
2006 | 1.57 | -10.85% |
2005 | 1.76 | -19.49% |
2004 | 2.18 | 72.36% |
2003 | 1.27 | 196.05% |
2002 | 0.4279 | -2.73% |
2001 | 0.4399 |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
![]() LHC Group LHCG | 2.32 | 105.51% | ๐บ๐ธ USA |
![]() National Healthcare
NHC | 0.8549 | -24.18% | ๐บ๐ธ USA |
![]() Chemed CHE | 3.76 | 233.52% | ๐บ๐ธ USA |